Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.39 | -1.80% | -0.03 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | -1.80% | |
Narrow Range Bar | Range Contraction | -1.80% | |
Inside Day | Range Contraction | -1.80% | |
Wide Bands | Range Expansion | -1.80% | |
Oversold Stochastic | Weakness | -1.80% | |
Pocket Pivot | Bullish Swing Setup | -5.48% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 2 days ago |
Bearish 180 Entry | 2 days ago |
Fell Below Previous Day's Low | 2 days ago |
Down 1% | 2 days ago |
Possible NR7 | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: Unknown
CERo Therapeutics Holdings, Inc. Description
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
Classification
Sector: Financial Services
Industry: Shell Companies
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.8 |
52 Week Low | 1.33 |
Average Volume | 1,347,240 |
200-Day Moving Average | 8.61 |
50-Day Moving Average | 2.41 |
20-Day Moving Average | 1.78 |
10-Day Moving Average | 1.53 |
Average True Range | 0.35 |
RSI (14) | 27.54 |
ADX | 30.64 |
+DI | 31.55 |
-DI | 20.96 |
Chandelier Exit (Long, 3 ATRs) | 2.72 |
Chandelier Exit (Short, 3 ATRs) | 2.37 |
Upper Bollinger Bands | 2.45 |
Lower Bollinger Band | 1.11 |
Percent B (%b) | 0.21 |
BandWidth | 75.20 |
MACD Line | -0.40 |
MACD Signal Line | -0.44 |
MACD Histogram | 0.0493 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.51 | ||||
Resistance 3 (R3) | 1.52 | 1.50 | 1.49 | ||
Resistance 2 (R2) | 1.50 | 1.47 | 1.49 | 1.48 | |
Resistance 1 (R1) | 1.44 | 1.45 | 1.43 | 1.43 | 1.48 |
Pivot Point | 1.42 | 1.42 | 1.41 | 1.41 | 1.42 |
Support 1 (S1) | 1.36 | 1.39 | 1.35 | 1.35 | 1.30 |
Support 2 (S2) | 1.34 | 1.37 | 1.33 | 1.30 | |
Support 3 (S3) | 1.28 | 1.34 | 1.29 | ||
Support 4 (S4) | 1.27 |